Journal
NEUROBIOLOGY OF AGING
Volume 71, Issue -, Pages 171-178Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2018.07.005
Keywords
Dementia with Lewy bodies; Alzheimer's disease; Atrophy; MRI
Categories
Funding
- Biogen
- Genilac
- IXICO
- Janssen
- Novartis
- Roche
- Sanofi-Genzyme
- Springer Healthcare
- Dutch Research Council (ZonMW) [733050509]
- Dioraphte
- Alzheimer Nederland
Ask authors/readers for more resources
We aimed to study if patients with dementia with Lewy bodies (DLB) who have concomitant Alzheimer's disease (AD) pathology (detected antemortem by cerebrospinal fluid [CSF] biomarkers) have additional loss of gray matter volume. Ninety-eight DLB patients were divided into a pure DLB (DLB/AD , n = 62) and a mixed DLB group (DLB/AD+, n = 36) and matched for age and symptom duration to 84 AD patients and 75 controls. We compared visual atrophy ratings, and in a subset, we analyzed cortical thickness and subcortical gray matter volumes. DLB/AD+ patients had more pronounced medial temporal lobe atrophy (MTA) compared to DLB/AD - (mean [total] MTA score 2.5 vs. 1.3, p = 0.02). Global and parietal atrophy scores were comparable between the 3 dementia groups and differed from controls. MTA score was associated with CSF A beta-42, while posterior cortical and global atrophy scores were associated with CSF tau. Cortical thinning was found in DLB/AD-, DLB/AD+, and AD compared to controls. Concomitant AD pathology seems to cause additional (hippocampal) atrophy in DLB, and this may contribute to a more devastating disease course in DLB/AD+ patients. (C) 2018 Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available